The OIG has added 18 reviews to its FY 2017 Work Plan – most of which target CMS programs, with a particular emphasis on prescription drug policies. For instance, the OIG now intends to examine the following Medicare and Medicaid topics (among others):
- Excessive Use of Opioids in Medicare Part D
- Including Non-Covered Versions When Setting Payment Amounts for Part B Drugs
- FDA Approval Status of Drugs in the Medicaid Drug Rebate Program
- Accuracy of Drug Classification Data Used to Collect Medicaid Rebates
- Reasonable Assumptions in Manufacturer AMP Reporting
- Review of Quality Measures Data Reported by Accountable Care Organizations in the Medicare Shared Savings Program
- Trends in Hospice Deficiencies and Complaints
Additional information about each of the new reviews is available on the OIG website.